The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
Authors:
- Tyler GutschenritterTGTyler Gutschenritter
- Vyshak A. VenurVVVyshak A. Venur
- Stephanie E. CombsSCStephanie E. Combs
- Balamurugan VellayappanBVBalamurugan Vellayappan
- Anoop P. PatelAPAnoop P. Patel
- Matthew FooteMFMatthew Foote
- Kristin J. RedmondKRKristin J. Redmond
- Tony J. C. WangTWTony J. C. Wang
- Arjun SahgalASArjun Sahgal
- Samuel T. ChaoSCSamuel T. Chao
- John H. SuhJSJohn H. Suh
- Eric L. ChangECEric L. Chang
Open Access
Abstract
Brain metastases are the most common intracranial malignant tumor in adults and are a cause of significant morbidity and mortality for cancer patients. Large brain metastases, defined as tumors with a maximum dimension >2 cm, present a unique clinical challenge for the delivery of stereotactic radiosurgery (SRS) as patients often present with neurologic symptoms that require expeditious treatment that must also be balanced against the potential consequences of surgery and radiation therapy—namely, leptomeningeal disease (LMD) and radionecrosis (RN). Hypofractionated stereotactic radiotherapy (HSRT) and pre-operative SRS have emerged as novel treatment techniques to help improve local control rates and reduce rates of RN and LMD for this patient population commonly managed with post-operative SRS. Recent literature suggests that pre-operative SRS can potentially half the risk of LMD compared to post-operative SRS and that HSRT can improve risk of RN to less than 10% while improving local control when meeting the appropriate goals for biologically effective dose (BED) and dose-volume constraints. We recommend a 3- or 5-fraction regimen in lieu of SRS delivering 15 Gy or less for large metastases or resection cavities. We provide a table comparing the BED of commonly used SRS and HSRT regimens, and provide an algorithm to help guide the management of these challenging clinical scenarios.Keywords
This publication has 83 references indexed in Scilit:
- A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life ResultsJournal of Clinical Oncology, 2013
- Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestationsBreast Cancer Research and Treatment, 2011
- Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosisRadiation Oncology, 2011
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- COMPARATIVE RISK OF LEPTOMENINGEAL DISSEMINATION OF CANCER AFTER SURGERY OR STEREOTACTIC RADIOSURGERY FOR A SINGLE SUPRATENTORIAL SOLID TUMOR METASTASISNeurosurgery, 2009
- The Linear-Quadratic Model Is an Appropriate Methodology for Determining Isoeffective Doses at Large Doses Per FractionSeminars in Radiation Oncology, 2008
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990